ClinicalTrials.gg
CompletedNCT01847898Updated Mar 14, 2017

Study on the Treatment of Osteoporotic Vertebral Fractures Using Vertebral Body Stenting

A Phase 4 interventional study of Vertebral Body Stenting (VBS) and Balloon Kyphoplasty in Vertebral Body Fractures, sponsored by Synthes GmbH. Completed at 5 sites in 2 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2017-03-14.

Sponsored by Synthes GmbH (part of Johnson & Johnson) · Phase 4, Interventional, and Treatment

Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Study summary

This is a randomized, controlled study to document and evaluate the clinical performance of the Vertebral Body Stenting (VBS) System in osteoporotic fractures of the thoracic and lumbar spine.

The randomized, controlled trial (RCT) will compare patients with VBS and Balloon Kyphoplasty.

02

Conditions studied

  • Vertebral Body Fractures

Keywords

  • Osteoporosis
  • Vertebral Body
  • Compression Fracture
  • Kyphoplasty
03

In context

Osteoporosis

1,601 studies on the registry are indexed under Osteoporosis; 209 are open to participants now.

This study's enrollment of 100 is above the median of 88 across 1,084 interventional studies indexed under Osteoporosis.

Browse Osteoporosis studies →

Lead sponsor

Synthes GmbH is the lead sponsor of 10 studies on the registry; none are open to participants now.

First submitted before Synthes GmbH became part of Johnson & Johnson.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 50
  2. 1 to 3 contiguous target vertebral compression fractures (VCF) meeting the following criteria:
  3. Fracture due to diagnosed or presumed underlying primary or secondary osteoporosis (Patients with AO type A1.x fractures and A3.1 fractures may be included in the study).
  4. All target VCFs are between Th5 and L5

    • All target VCFs to be treated show either:

      • Height change: An acute (\< 6 month) change in VB height (>15% height loss) with height loss at the anterior, middle or posterior portion of the VB consistent with a worsening of 1 or more grades by the Genant criteria, OR
      • Positive MRI or bone scan: VB shows hyperintense signal on MRI-T2 or STIR sequence or target VB is positive on radionuclide bone scan
    • Back pain correlating with the location of at least one VCF
  5. Treatment of all target VCFs is technically feasible by and clinically appropriate for BOTH vertebroplasty and balloon kyphoplasty
  6. No major surgery to the spine planned for at least 1 month following enrollment
  7. Pre-treatment back pain by numerical rating scale (NRS) score >= 4 (0-10 scale)
  8. Subject is able to understand the risks and benefits of participating in the study and is willing to provide written
  9. Psychosocially, mentally and physically able to fully comply with the protocol requirements for the duration of the study including adhering to scheduled visits, treatment plan, completing forms and other study procedures

Exclusion criteria

Exclusion Criteria:

  1. VB morphology or configuration is such that either balloon kyphoplasty OR vertebroplasty is not technically feasible for the targeted VCFs
  2. Fracture due to high-energy trauma
  3. Suspected OR proven cancer inside index vertebral body.
  4. Disabling back pain due to causes other than acute fracture (e.g., sacroiliac fracture, symptomatic degenerative disc disease, lumbar spinal stenosis)
  5. Any painful VCF with fracture age > 6 months
  6. Patients with primary tumors of the bone (e.g., osteosarcoma) or solitary plasmacytoma at site of the index VCF. Patients with these tumors in anatomic sites other than the index VCF are eligible.
  7. Any objective evidence of neurologic compromise at baseline
  8. Previous balloon kyphoplasty or vertebroplasty for any VCF
  9. Spine stabilization beyond balloon kyphoplasty or vertebroplasty required for targeted VCFs
  10. Significant clinical comorbidity that may potentially interfere with long-term data collection or follow-up (e.g., dementia, severe comorbid illness)
  11. Patients requiring the use of high-dose (>= 100mg prednisone or 20 mg dexamethasone per day), IV pain medication, or nerve block to control chronic back pain unrelated to index VCF(s). Patients who receive high-dose steroids for treatment of their cancer (for at least 30 days) are eligible.
  12. Patients who may require bone marrow transplantation during the course of the study
  13. Spinal cord compression or canal compromise requiring decompression
  14. Patients with osteoblastic tumors at the site of index VCF. Patients with osteoblastic tumors of vertebral levels not intended for kyphoplasty may be enrolled.
  15. MRI (e.g. cerebral aneurysm clips, pacemaker, implanted biostimulators, cochlear implants, penile prosthesis)
  16. Spinal instability as indicated by neurologic deficit, kyphosis >30°, compression >50%, translation > 4 mm, interspinous-process widening.
  17. Pre-existing conditions contrary to either balloon kyphoplasty or vertebroplasty, such as:

    • Irreversible coagulopathy or bleeding disorder. Note regarding reversible coagulopathies: Subjects on coumadin or other anticoagulants may participate. Investigators should follow routine practices for perioperative discontinuation and re-initiation of anticoagulants.
    • Allergy to any device materials (e.g., bone cement) for balloon kyphoplasty or vertebroplasty. Note that in subjects with allergy to iodine-based contrast, other non-iodine contrast solutions may be used.
    • Any evidence of VB or systemic infection
  18. Pregnant or
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Vertebral Body Stenting (VBS)

    Procedure: Vertebral Body Stenting (VBS)

  • Experimental
    Balloon Kyphoplasty

    Procedure: Balloon Kyphoplasty

Interventions

  • ProcedureVertebral Body Stenting (VBS)

    Vertebral Augmentation with a Stent

  • ProcedureBalloon Kyphoplasty

    Vertebral Augmentation with a Balloon (device not specified)

06

What researchers measure

Primary outcomes

  1. Increase and maintenance of the vertebral body height

    The anterior edge, mid height and posterior edge of the index vertebral body are measured pre-operatively standing, after prone intraoperative positioning on the table (dynamic fracture mobility), intra-operatively following balloon dilation (height restoration), after balloon deflation and removal, after cement deposition, and finally postoperative standing. Anterior, middle and posterior height measurements will be made at each time-point during the study to measure maintenance of vertebral body height over time. The ratio between anterior and mid or posterior edge height (Beck-index) is calculated to avoid the problem of image calibration. In addition, the relative height fractions in comparison to the nearest healthy vertebral body (referent level) are calculated. Finally, local and regional sagittal angles and overall lumbar lordosis or thoracic kyphosis, respectively, are assessed for measurement of improvement of alignment.

    Time frame: 12 months

  2. Visual analog scale (VAS) for back pain

    Pain assessment by the patients using the VAS back pain from 0 to 10. In this scale 0 means "no pain" and 10 is the "worst pain imaginable". A pre- to postoperative difference of at least 2 observed during the course of the therapy is regarded as clinically relevant.

    Time frame: 12 months

  3. Adverse events

    * Any re-operations, revisions, and removals or supplemental fixation at the index level(s) is considered a study failure. * Any intra-operative system malfunction, misplacement of the balloon or stent, balloon or stent fracture, or failure of the balloon or stent to fully deploy is considered a study failure.

    Time frame: 12 months

Secondary outcomes

  1. Radiographic evaluations

    Evaluation of osteolysis surrounding the VBS System and/or cement; Evaluation of adjacent level arthritis; Evaluation of bridging trabecular bone at intradiscal spaces adjacent to the treated level(s); Assessment of segmental kyphosis/lordosis at the treated and adjacent level(s) Evaluation of all vertebral body fractures directly above and below the treated level(s

    Time frame: 2 years

  2. Global assessment by the patient using the VAS

    Patients globally assess their overall satisfaction with the treatment using the VAS, where 0 = totally dissatisfied and 10 = totally satisfied. A six-level question comparing the current situation to the preoperative state of health is also used.

    Time frame: 2 years

  3. VAS leg pain

    VAS leg pain from 0 to 10. In this scale 0 means "no pain" and 10 is the "worst pain imaginable".

    Time frame: 2 years

  4. Analgesic usage

    Analgesic consumption is documented in the categories - none, Paracetamol (Acetaminophen), Nonsteroidal anti-inflammatory drugs (NSAID), Metamizole, mild opiates and strong opiates at baseline and each follow-up office visit. This information is obtained with the help of medical staff or the patient's family and relatives.

    Time frame: 2 years

  5. Neurological assessment of root tension signs, muscle strength, sensory deficit and reflexes

    Assessment of root tension signs (yes/no), muscle strength (normal/decreased), sensory deficit (yes/no) and reflexes (normal/decreased/increased) will be conducted at baseline and each follow-up visit

    Time frame: 2 years

  6. Symptoms associated with position/direction of cement extrusion

    Symptoms associated with position/direction of cement extrusion: epidural, pulmonary, intradiscal, large vessels, foraminal, paraspinal soft tissue, paravertebral vessels, other.

    Time frame: 2 years

  7. Disability using the Oswestry Disability Index (ODI)

    Oswestry Disability Index (ODI), version 2.1 will be used.

    Time frame: 2 years

  8. Quality of Life Evaluation using the EuroQol, general quality of life questionnaire (EQ-5D)

    The EQ-5D (EuroQol, general quality of life questionnaire) will be used.

    Time frame: 2 years

07

Study locations

5 sites
  • Universitätsklinik für Unfallchirurgie
    Graz, Austria
  • AKH
    Wien, Austria
  • Universitätsklinikum Schleswig-Holstein
    Kiel, Germany
  • Universitätsklinikum
    Münster, Germany
  • Universitätsklinik und Poliklinik für Chirurgie
    Rostock, Germany
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 14, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01847898
Lead sponsor
Synthes GmbH
Responsible party
Sponsor
First posted
May 7, 2013
Start date
Sep 1, 2009
Primary completion
Dec 31, 2015
Completion
Dec 31, 2015
Last update
Mar 14, 2017

Study contacts

Paul F. Heini, Prof. Dr. med.
principal investigator · Klinik Sonnenhof, Bern, Switzerland

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion